Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Iterum Therapeutics Q1 Adj. EPS $(0.10) Beats $(0.14) Estimate

Author: Benzinga Newsdesk | May 13, 2025 06:01am
Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 73.68 percent increase over losses of $(0.38) per share from the same period last year.

Posted In: ITRM

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist